Daiichi Sankyo和GSK将在日本成立疫苗合资企业

Pharmadeals Review Pub Date : 2012-03-14 DOI:10.3833/PDR.V2012I3.1699

Heather Cartwright

{"title":"Daiichi Sankyo和GSK将在日本成立疫苗合资企业","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I3.1699","DOIUrl":null,"url":null,"abstract":"Daiichi Sankyo and GlaxoSmithKline have agreed to form a 50-50 joint venture for the development and distribution of vaccines in Japan. The joint venture, which will be named Japan Vaccine and which will commence business in July 2012 with an initial capitalisation of ¥100 M (US$1.2 M), will inherit development and commercialisation rights to prophylactic vaccines from both parent companies. Its business will later be expanded as new vaccines from the pipeline are approved.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"94 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Daiichi Sankyo and GSK to Establish Vaccines Joint Venture in Japan\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I3.1699\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Daiichi Sankyo and GlaxoSmithKline have agreed to form a 50-50 joint venture for the development and distribution of vaccines in Japan. The joint venture, which will be named Japan Vaccine and which will commence business in July 2012 with an initial capitalisation of ¥100 M (US$1.2 M), will inherit development and commercialisation rights to prophylactic vaccines from both parent companies. Its business will later be expanded as new vaccines from the pipeline are approved.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"94 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I3.1699\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I3.1699","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

第一三共(Daiichi Sankyo)和葛兰素史克(GlaxoSmithKline)已同意成立一家对半持股的合资企业，在日本开发和分销疫苗。该合资企业将被命名为日本疫苗，将于2012年7月开始营业，初始资本为1亿日元(120万美元)，将从两家母公司继承预防性疫苗的开发和商业化权利。随着管线中的新疫苗获得批准，该公司的业务将进一步扩大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Daiichi Sankyo and GSK to Establish Vaccines Joint Venture in Japan

Daiichi Sankyo and GlaxoSmithKline have agreed to form a 50-50 joint venture for the development and distribution of vaccines in Japan. The joint venture, which will be named Japan Vaccine and which will commence business in July 2012 with an initial capitalisation of ¥100 M (US$1.2 M), will inherit development and commercialisation rights to prophylactic vaccines from both parent companies. Its business will later be expanded as new vaccines from the pipeline are approved.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量